High materiality9/10
Insmed (INSM) PT Lowered to $207 at BofA Securities
Why it may matterVerify against the original reporting
Buy
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Analyst target update: $207 target vs current price $100.60; implied upside ~106%; bullish.
- Target $207 vs price $100.60; upside ~106%.
Key facts
- 01
Target: $207
- 02
Posted price: $100.6
- 03
Analyst firm: Raymond James
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.